Selected Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2016

Quarterly Financial Information Disclosure [Abstract]

Selected Quarterly Financial Data

	Fiscal Year 2016 Quarters
	1st			2nd			3rd			4th			Total
Revenues(1)	$	4		$	97		$	5,268		$	11,962		$	17,331
Gross profit(2)	$	—		$	(429	)	$	4,423		$	10,258		$	14,252
Net loss	$	(49,762	)	$	(71,322	)	$	(71,613	)	$	(78,696	)	$	(271,393	)
Basic and diluted net loss per share(3)	$	(0.45	)	$	(0.63	)	$	(0.61	)	$	(0.65	)	$	(2.34	)

	Fiscal Year 2015 Quarters
	1st			2nd			3rd			4th			Total
Revenues	$	4		$	1		$	39		$	17		$	61
Gross profit	$	—		$	—		$	—		$	—		$	—
Net loss	$	(40,375	)	$	(39,378	)	$	(38,906	)	$	(45,784	)	$	(164,443	)
Basic and diluted net loss per share(3)	$	(0.40	)	$	(0.39	)	$	(0.39	)	$	(0.45	)	$	(1.63	)

(1) The Company commenced commercial sales of NUPLAZID in May 2016. The quarters ended June 30, 2016, September 30, 2016, and December 31, 2016 reflect net product revenue related to NUPLAZID.

(2) Determined by subtracting cost of product sales from product sales, net.

(3) Net loss per common share, basic and diluted, are computed independently for each quarter and the full year based upon respective average shares outstanding. Therefore, the sum of the quarterly net loss per common share amounts may not equal the annual amounts reported.